PBMs commit to showing TrumpRx cash prices alongside insurance prices in prescribing tools

The Pharmaceutical Care Management Association and ten pharmacy benefit managers have committed to showing TrumpRx cash prices next to the price a patient would pay through their pharmacy benefit, using the real-time benefit tools that doctors already use when prescribing ^[1].

The commitment was made in coordination with the Centers for Medicare and Medicaid Services and was described in a PCMA blog post published August 20, 2026, which says the pledge itself was announced the previous week ^[1]. In the pledge, PCMA and the PBMs say they "commit to supporting the goals of transparency and affordability by presenting to patients the cash prices listed on TrumpRx for comparison to the prices under their benefit, through use of PBM real time benefit tools, when consistent with plan coverage and allowed by law" ^[1].

CMS Administrator Dr. Mehmet Oz applauded the commitment, saying, "By making negotiated drug prices available alongside cash prices on TrumpRx, this agreement will give patients greater visibility into how much they're paying and help them find the best possible deal" ^[1]. PCMA says that viewing prescription costs outside a pharmacy benefit is uncommon today and that the information can be hard for patients and doctors to find ^[1].

What the prices look like

Real-time benefit tools let a prescriber see a patient's costs for several drugs that treat the same condition and discuss lower-cost options ^[1]. Under the commitment, those tools would also show the TrumpRx cash price for a drug when one is listed there ^[1].

TrumpRx currently features several GLP-1 medications with cash prices listed beside higher "original" prices: the Wegovy pill at $149 a month against $1,349, the Wegovy pen at $199 a month against $1,349, Ozempic at $199 a month against $1,028, and Zepbound at $299 a month against $1,087 ^[2]. Ozempic and Wegovy are brand names for semaglutide; Zepbound is tirzepatide ^[2]. Mounjaro, Rybelsus and Foundayo are not among the GLP-1 listings shown on the site ^[2].

The site says it has saved Americans more than $700,000,000 and describes its pricing as most-favored-nation pricing ^[2].

Why it matters for patients

For people taking GLP-1 medications, the featured cash prices on TrumpRx are hundreds of dollars a month below the original prices shown for the same products ^[2]. If those prices appear inside prescribing tools, a patient and their doctor could see both numbers at the moment a prescription is written rather than after a claim is run at the pharmacy counter ^[1].

The commitment is conditional. PCMA says prices will be presented "when consistent with plan coverage and allowed by law," so the comparison may not appear for every drug or every plan ^[1]. PCMA also states that a patient's cost will often be lowest through their pharmacy benefit, and that there are times when TrumpRx is lower ^[1].

The announcement does not address how paying a cash price instead of using insurance would affect a deductible or an out-of-pocket maximum, and it does not say whether cash programs run by manufacturers, such as LillyDirect or NovoCare, would be shown in the same tools. Those details have not been reported.

What happens next

No start date has been disclosed for when TrumpRx prices will appear in real-time benefit tools, and the ten pharmacy benefit managers that signed the commitment have not been named in PCMA's account ^[1]. PCMA describes the commitment as building on existing tools that already deliver real-time cost information through online portals, mobile apps and other digital tools, but it gives no timeline for the change ^[1].